Response and survival predictors in a cohort of 319 patients with Waldenstr€om macroglobulinemia treated with ibrutinib monotherapy

Jorge J. Castillo, Shayna R. Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly R. Leventoff, Timothy P. White, Kirsten Meid, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Zachary R. Hunter, Christopher J. Patterson, Andrew R. Branagan, and Steven P. Treon

Response and survival predictors in a cohort of 319 patients with Waldenstr€om macroglobulinemia treated with ibrutinib monotherapy

Submitted 7 September 2021; accepted 6 December 2021; prepublished online on Blood Advances First Edition 29 December 2021; final version published online 4 February 2022. DOI 10.1182/bloodadvances.2021006106